Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: Diagnostic value for birch pollen and associated allergies

Pauli, G.; Oster, J.P.; Deviller, P; Heiss, Suzanne; Bessot, J.C.; Susani, Markus; Ferreira, Fátima; Kraft, Dietrich; Valenta, Rudolf

doi:10.1016/s0091-6749(96)70264-6

Cited by 171 publications

(109 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sensitization to profilin was 21.0% of all pollen sensitized individuals. This percentage is similar to that observed by Valenta et al (1992) in their first report of profilin as a plant panallergen (20%) and by Pauli et al (1996) using rBetv2 for SPT (19.6%). However Asero et al (2008) found a higher proportion of sensitization to date palm profilin (30%) in patients sensitized to pollens.…”

Section: Discussionsupporting

confidence: 88%

“…However, the fine specificity of IgE directed to variable epitopes may influence the clinical manifestation of profilin sensitization (Radauer et al, 2006). Natural profilin seems to be better for diagnosis than its recombinant counterpart both in vitro and in vivo, possibly because of improper folding of the recombinant molecule, as shown for rBet v 2 and nBet v 2 (van Ree et al, 1999;Pauli et al, 1996;Elfman et al, 1997;Wensing et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sensitization to profilin in the Central region of Portugal

Tavares

Machado

Loureiro

et al. 2008

Science of The Total Environment

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Sensitization to profilin in the Central region of Portugal

Tavares

Machado

Loureiro

et al. 2008

Science of The Total Environment

View full text Add to dashboard Cite

“…The evaluation of' recombinant allergens should ideally demonstrate 1) IgE-binding capacity (14,15) 2) ability to stimulate specific T cells (16) 3) capacity to induce specific basophil degranulation (17) 4) induction of IgE responses in experimental animal systems (18-20) 5) induction of skin reactivity in man (21)(22)(23)(24)(25)(26).…”

Section: Strategies For Obtaining Recombinant Allergensmentioning

confidence: 99%

“…While previous studies on the role of allergenspecific IgG antibody responses were hampered by the lack of well-defined allergen preparations, purified recombinant allergens have now become available for measurements with defined components. Studies performed with recombinant Bet v 1 (23,24), the major birch pollen allergen, recombinant timothy grass-pollen allergens (Phi p 1, Phi p 2, and Phi p 5) (76), and recombinant Der f 2 (77,78) established the following points: 1) sera from allergic and nonallergic subjects contained allergen-specific IgG antibodies belonging to different subclasses 2) levels of allergen-specific IgE are poorly correlated with IgG subclass responses 3) with epitopes prepared from major allergens by recombinant DNA technology, it could be shown that IgE and IgG antibodies of allergic patients bind to the same and also different epitopes (78).…”

Section: Ige-binding Haptens From Major Allergens and Allergen-specifmentioning

confidence: 99%

Recombinant allergens

Valenta

Vrtala

Laffer

et al. 1998

Allergy

View full text Add to dashboard Cite

A great variety of recombinant plant, mite, mold, mammal, and insect allergens have been expressed in heterologous hosts (e.g., Escherichia coli), their cDNA being used as a template. The number of biologically active recombinant allergens available for experimental, diagnostic, and therapeutic purposes is increasing tremendously. Recombinant allergens have proven to be valuable tools to investigate T‐cell and B‐cell recognition of allergens as well as to study mechanisms of specific IgE regulation. The immunologic equivalence of many relevant recombinant allergens with their natural counterparts has been demonstrated, and the three‐dimensional structures of several recombinant allergens have been described recently. As a result of extensive cross‐reactivities among the relevant allergens, it appears that the number of epitopes needed for diagnosis and specific immunotherapy is less diverse than originally anticipated and might be soon covered by recombinant molecules. Recombinant allergens have been used for successful in vitro, as well as in vivo, allergy diagnosis, and work is in progress to produce recombinant allergen derivatives with reduced anaphylactic potential to improve current forms of immunotherapy.

show abstract

“…One may reasonably suppose that the in vitro cross-reactivity may be reproduced in vivo using pollen extracts, but when we tested this hypothesis by performing oral challenges with birch and grass pollen extracts in patients with pollen-induced rhinoconjunctivitis and OAS from apple, celery, and tomato, the patients did not react to the challenge (11). The availability of recombinant Bet v 1 to be used for SPT achieved a high diagnostic value in patients with the birch-apple syndrome and other related food allergies as well (25). Thus, in order to verify whether a low concentration of epitopes cross-reacting with foods may account for the lack of response to oral challenge with pollen extracts, we repeated the challenges in patients with pollinosis and OAS, and in healthy controls, using, along with commercial extracts, the recombinant allergens rBet v 1 and rPhl pi, which served as material also for SPTs and nasal challenges.…”

Section: Discussionmentioning

confidence: 99%

Sublingual Reactivity to rBET V1 and rPHL P1 in Patients with Oral Allergy Syndrome

Marcucci

Sensi

Cara

et al. 2006

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Oral Allergy Syndrome (OAS) in patients with pollen-induced rhinoconjunctivitis is caused by specific IgE recognizing cross-reacting epitopes of fruits and plants, which were clearly shown in vitro, but failed to be demonstrated in vivo by cross-challenges in the target organs. Considering the hypothesis of degradation of such epitopes in natural extracts, challenges with recombinant pollen allergens were done to evaluate the reactivity of the oral mucosa in OAS patients. Seventeen patients with OAS and rhinitis from birch (10) and grass pollen (7) and 10 non-atopic controls were studied by skin prick tests (SPT), allergen specific nasal challenges (ASNC) and allergen specific sublingual challenges (ASSC) with birch and timothy extracts and with rBet vl and rPhl pt at increasing concentrations from 1 to 1000 meg/mi. None of the healthy subjects in the control group had any positive test for birch and timothy extracts or for recombinant allergens. In the OAS group the following results were observed: SPTs with recombinant allergens were positive in all patients, mostly at 10 mcg/ml concentration; ASNC with rBet vl were positive in all patients, mostly at 100 mcg/ml; ASSC with natural pollen extracts were positive in only 2 of 17 patients, but in 15 of'17 with rBet vl and rPhl pt, mostly at 500 mcg/ml and 1000 meg/mi. ASSC with rBet vi and rPhl p l were positive with a mean concentration of 677 and 533 mcg/ml, respectively. The results of sublingual challenges with rBet vl and rPhl pt showed the in vivo cross-reactivity between pollens and foods in patients with OAS, but high concentrations ofthe recombinant allergens were needed to reproduce oral symptoms, thus explaining the failure of challenges performed with natural extracts, which have concentrations of major allergens lower than 50 meg/mi. This indicates that sublingual mucosa is much less reactive to allergens than other surfaces, such as skin and nasal mucosa, probably because of its anatomic and immunologic peculiarity.Oral allergy syndrome (OAS) is a condition characterized by oral swelling and itching after the contact of specific foods with the oral mucosa (1). In most cases this syndrome occurs in patients with pollen-induced rhinoconjunctivitis when eating fresh fruits or vegetables (2-4). The etiology ofOAS is generally attributed to cross-reactivity between some food allergens and some inhalant allergens. The contact with the inhaled allergen leads to sensitization of upper and lower airways, with a production of specific IgE cross-reactive to food allergens, which, in turn, are responsible for the oral

show abstract

Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: Diagnostic value for birch pollen and associated allergies

Cited by 171 publications

References 21 publications

Sensitization to profilin in the Central region of Portugal

Sensitization to profilin in the Central region of Portugal

Recombinant allergens

Sublingual Reactivity to rBET V1 and rPHL P1 in Patients with Oral Allergy Syndrome

Contact Info

Product

Resources

About